Navigation Links
Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals
Date:10/26/2011

HORSHAM, Pa., Oct. 26, 2011 /PRNewswire/ -- Galleon Pharmaceuticals, a leader in the pharmaceutical treatment of breathing-control disorders, announced today that its board of directors has elected Thomas J. Dietz, Ph.D., as the company's chairman.  Dr. Dietz is chairman and CEO of Waypoint Holdings, LLC, a diversified financial-holdings and services company.  

Previously, Dr. Dietz was co-CEO and then CEO and a director of Pacific Growth Equities, LLC, a San Francisco-based investment bank and institutional brokerage firm from 2004 to 2009, when the firm was acquired by Wedbush Securities.  Dr. Dietz served as head of the investment banking division at Wedbush until November 2010.  

Prior to taking the CEO role at Pacific Growth, Dr. Dietz served as the company's director of equities research and was an award-winning biotechnology and biopharmaceutical analyst.  He joined Pacific Growth in 1993.  Previously, he was a member of the research faculty in the Department of Medicine, University of California, San Francisco and the VA Medical Center.  Dr. Dietz is a member of several national societies and currently serves on the boards of trustees of several non-profit organizations, including the West Bay Region board of the Sutter Health System that includes California Pacific Medical Center, San Francisco.  

Dr. Dietz holds a Ph.D. in molecular biology and biochemistry from Washington University, St. Louis, and was a National Science Foundation Post-Doctoral Fellow.  

About Galleon Pharmaceuticals

Galleon is the first pharmaceutical company to focus primarily on the drug treatment of breathing-control disorders.  Its initial goals are to improve the safety, efficacy and economics associated with the acute care of surgical patients and longer-term care of patients with conditions such as moderate-to-severe pain or sleep apnea.  In the United States alone, it is estimated that 100 million patients are at risk for a breathing-control disorder due to drugs, diseases or genetics.

The company's product pipeline reflects recent advances in neurobiology, molecular biology and respiratory medicine which have enabled the development of a unique drug-discovery platform and promising drug candidates that are now undergoing clinical trials.  Galleon's integrated discovery and development approach is unique among pharmaceutical companies and enables the rapid evaluation of multiple variables to establish a comprehensive profile of breathing-control activity.  For more information, please visit www.galleonpharma.com.  


'/>"/>
SOURCE Galleon Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph.D., Awarded the 2009 Nobel Prize in Chemistry
2. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
3. K-V Pharmaceutical Names Thomas McHugh Chief Financial Officer
4. Accera, Inc. Appoints Dr. Thomas Werner President & CEO and Announces FDA Acceptance of IND Application for AC-1204 for Mild-to-Moderate Alzheimers Disease
5. Excaliard Pharmaceuticals Appoints Thomas Wiggans to Chairman of the Board
6. MAP Pharmaceuticals Appoints Thomas P. McCracken as Vice President, Intellectual Property
7. Osteotechs Plexur M® Technology Wins Thomas Alva Edison Patent Award from the New Jersey Research and Development Council
8. PharMEDium Hires Thomas W. Rasnic as Vice President, Quality, Regulatory Affairs and Research and Development
9. Symmetry Medical Board of Directors Appoints Thomas J. Sullivan President and Chief Executive Officer
10. Solta Medical, Inc. Appoints Thomas J. Yorkey, Ph.D. to Vice President of Research & Development
11. Thomas, McNerney & Partners Expands Team and Moves West Coast Office to San Diego
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Calif. , Feb. 4, 2016  Edwards Lifesciences ... patient-focused innovations for structural heart disease and critical care ... accelerated share repurchase (ASR) agreement with Morgan Stanley & ... stock.  This repurchase is part of the Company,s previously ... the Company,s common stock.  --> ...
(Date:2/4/2016)... Feb. 4, 2016 Worldwide Radiology Oncology ... growth as next generation systems provide a way ... for cancer surgery. New systems pinpoint the delivery ... has been such a problem previously, limiting the ... robots take cancer surgery far beyond what has ...
(Date:2/4/2016)... Calif. , Feb. 4, 2016  SciClone ... today announced it has entered into a settlement ... Commission (SEC) fully resolving the SEC,s investigation into ... (FCPA).  Under the terms of the settlement agreement, ... $12.8 million, including disgorgement, pre-judgment interest and a ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President Joe ... signed a joint enrollment and degree completion agreement. The agreement, which begins ... degrees at FHU|Dickson. , The agreement allows students to be jointly admitted ...
(Date:2/5/2016)... ... February 05, 2016 , ... In the fourth ... country gathered at the La Valencia Hotel in San Diego, California to discuss ... named the year’s most outstanding franchise, walking away with the coveted David Wright ...
(Date:2/5/2016)... SARASOTA, Fla., (PRWEB) , ... February 05, 2016 , ... ... appetizing recipes just in time for this weekend’s Big Game. Take the stress out ... ingredients that will keep your guests happy at every stage of the game. , ...
(Date:2/5/2016)... ... February 05, 2016 , ... Stuart Bentkover, MD, FACS is ... to provide the most effective tattoo removal today, Dr. Bentkover is the only doctor ... by Cynosure, the PicoSure has been approved by the Food and Drug Administration (FDA) ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a topic that should ... event they are experiencing an illness. Migraines are a severe form of a headache ... migraines would not wish the pain on their worst enemy, the feeling can last ...
Breaking Medicine News(10 mins):